Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
In Brief

Kelly Norsworthy named acting associate director for research mentorship in FDA’s Oncology Center of Excellence

January 19, 2024
Vol.50 No.03
Drugs & Targets

FDA approves Keytruda + chemoradiotherapy for FIGO 2014 stage 3-4A cervical cancer

January 19, 2024
Vol.50 No.03
Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approval
Regulatory News

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approval
Meanwhile, NCI trial will assess clinical utility

January 12, 2024
Vol.50 No.02
By Jacquelyn Cobb
Drugs & Targets

FDA approves Welireg for advanced renal cell carcinoma

January 05, 2024
Vol.50 No.01
Drugs & Targets

FDA approves Padcev + Keytruda for locally advanced or metastatic urothelial cancer

January 05, 2024
Vol.50 No.01
FDA, Friends identify next steps for dose optimization, pragmatic trials, academic-led studies for drug approvals

FDA, Friends identify next steps for dose optimization, pragmatic trials, academic-led studies for drug approvals

December 15, 2023
Vol.49 No.46
By Matthew Bin Han Ong
Drugs & Targets

FDA approves Welireg for advanced renal cell carcinoma

December 15, 2023
Vol.49 No.46
Drugs & Targets

FDA approves Iwilfin for adult and pediatric patients with high-risk neuroblastoma

December 15, 2023
Vol.49 No.46
As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

December 08, 2023
Vol.49 No.45
By Matthew Bin Han Ong
Drugs & Targets

FDA approves Jaypirca in CLL/SLL indications

December 08, 2023
Vol.49 No.45

Posts navigation

Previous1…414243…63Next

Trending Stories

  • Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
  • Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%
  • Is it time to re-assess the practice and practicality of screening colonoscopy?
    Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives
  • The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection
  • Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
    “There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns
  • Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there?

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account